Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149871 (deep vein thrombosis)
 12,364 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A combined prophylaxis against postoperative deep venous thrombosis comprising of sequential pneumatic limb compression using RMP I/K apparatus and lysine or dextran 70.000 administration was of applied in 34 patients after total hip arthroplasty. In 14 cases lysine was the drug, dextran was used in remaining ones. Prophylaxis was evaluated by impedance plethysmography. No case of postoperative deep venous thrombosis was reported.
Chir Narzadow Ruchu Ortop Pol 1990
PMID:[Rhythmic pneumatic compression of the limb as a contributing element of postoperative deep vein thromboembolism prophylaxis in patients after orthopedic surgery]. 128 46

On the basis of the hemocoagulation and hemostasis parameters study the actual hemostasis state was evaluated in 30 patients treated for active deep venous thrombosis (DVT) in dependence on its extent. In comparison with 30 healthy persons there were found statistically significant changes in a majority of laboratory parameters that can indicate thrombophilic state. Platelet activation, increased coagulation system activity, decreased fibrinolytic activity as well as increased fibrinogen and fibrin degradation products were demonstrated. The positive correlation between the extent of DVT and the relevance of hemostasis changes was revealed which results to these conclusions: the more extensive DVT--the more intensive tendency to thrombophilia up to intravascular blood coagulation activation was observed. Although the adequate prolongation of the prothrombin time (during the coumarin therapy) or APTT (during the heparin therapy) was achieved, the laboratory parameters showed a therapy insufficiency. In the cases of laboratory signs of the activated intravascular blood coagulation we can recommended a fortification of the oral anticoagulant therapy by its combination with antiplatelet drugs or by its temporary replacement by the heparin therapy.
Mater Med Pol
PMID:Evaluation of blood coagulation tests in deep venous thrombosis. 130 56

In a multicenter randomized trial, the efficacy and safety of two streptokinase (SK) dosage regimens have been evaluated in patients with proximal deep vein thrombosis of inferior limbs. Twenty-nine patients received SK by a continuous intravenous infusion (250,000 IU as initial dose, 100,000 IU/h as maintenance dose), and 26 patients were treated with intermittent SK administration (500,000 IU as initial dose, followed by 250,000 IU every 12 h). Thrombolytic therapy was continued for 4 days, then the patients received heparin for 5 days and oral anticoagulant for 3 months. The results of treatment as judged by phlebographic examinations were similar in the two groups. Complete, substantial or partial thrombolysis was achieved in 52% of patients in the continuous infusion group and in 58% of patients in the intermittent treatment group. During SK administration, major bleeding complications occurred in 6 patients treated by continuous infusion and in 2 of the second group. The results showed that the intermittent SK administration is as effective and safe as the method of continuous SK infusion in the treatment of deep vein thrombosis.
Pol Tyg Lek
PMID:[Continuous intravenous infusion versus intermittent administration of streptokinase in patients with deep venous thrombosis of the lower extremity]. 166 37

Ninety-four patients with deep vein thrombosis of inferior limbs were randomly allocated to receive sodium heparin either by subcutaneous injections or by continuous intravenous infusion for six days. No significant difference was observed in the therapeutic efficiency as judged by phlebographic examinations and in rate of symptomatic pulmonary embolism between the two groups. There was one instance of major bleeding in the subcutaneous group. Minor bleedings occurred in 10 of the 48 patients treated with subcutaneous heparin and in 13 of the 46 patients receiving intravenous heparin. The results showed that subcutaneous injections of sodium heparin are as effective and safe as continuous intravenous infusion of this drug in the treatment of deep vein thrombosis.
Pol Tyg Lek
PMID:[Subcutaneous injections and intravenous infusion of sodium salt of heparin in the treatment of thrombosis of deep veins of the lower extremities]. 210 38

The study was carried out of 53 patients with acute myocardial infarction receiving no anticoagulant treatment. Changes were traced in certain indices of the blood clotting system and fibrinolysis in plasma in the first 14 days of the disease, with particular attention given to patients in whom during the hospitalization signs of deep vein thrombosis in the lower extremities appeared or a positive result was obtained of the test with 125I-fibrinogen. In a group of 9 patients with deep vein thrombosis developing during the observation, on the first day of myocardial infarction shortening of the kaolin-cephalin clotting time and considerable rise of the level of fibrinogen-fibrin (FDP) degradation products were noted in serum, and on the 14th day raised fibrinogen level and reduced exogenous fibrinolytic activity of the plasma were noted. Increased level of fibrinogen and FDP and exogenous and endogenous plasma fibrinolytic activity observed on the 7th day of the disease were not related to the development of thrombotic complications. The thrombin clotting time, platelet count, factor X level, protein C concentration and antithrombin III activity in the plasma were not significantly changed during myocardial infarction. The obtained results suggest a limited usefulness of the basic tests of the clotting and fibrinolytic systems for early diagnosis of deep vein thrombosis in acute myocardial infarction.
Pol Arch Med Wewn 1990 Aug
PMID:[Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis]. 227 86

In 10 patients with thromboembolic disease 1 Gunther filter and 9 LGM filters were inserted. Indications for filter placement were: pulmonary hypertension caused by recurrent pulmonary embolism in 3 cases; planned surgery in 2 patients with pulmonary embolism and deep venous thrombosis; recurrent pulmonary embolism despite of anticoagulant treatment in 2 cases, previously performed thrombo-endarterectomy in 1 case; contraindications for anticoagulant treatment in 1 case and complications of anticoagulant therapy also in 1 case. No serious complications after filter placement were observed.
Pneumonol Alergol Pol 1995
PMID:[Indications for prophylactic vena cava filters introduced subcutaneously in patients with thromboembolic disease--preliminary report]. 758 Oct 62

Oral anticoagulants are generally accepted as secondary prophylaxis in patients with thromboembolic disease. Long term oral anticoagulant treatment of 24 survivors of clinically acute massive pulmonary embolism (AMPE) was assessed. There were following indications for such a treatment: recurrent PE/DVT in history and/or continuous risk factors. In the group of survivors of AMPE with continuing risk factors or the recurrence of that disaster the long-term oral anticoagulant therapy is effective, relatively safe and therefore justified.
Pneumonol Alergol Pol 1994
PMID:[Secondary prevention by using oral anticoagulants in patients with clinically acute massive pulmonary embolism]. 806 40

Among the risk factors of venous thromboembolism malignant neoplasms play a very important role. 43-years old man with adenocarcinoma of the lung, neoplasmatic cardiac tamponade and recurrent deep venous thrombosis has been presented. The pitfalls in diagnosis and particularly in treatment of venous thromboembolism in cancer-patients have been discussed.
Pneumonol Alergol Pol 1994
PMID:[Lung neoplasms with pericardial metastasis, complicated by venous thromboembolism: case report]. 806 48

In the case of 53 years old woman LGM filter was inserted over renal veins. Indications for those procedures were: vena cava thrombosis in distal part of vena cava what not allowed to place filter below renal veins, malignancy, planned surgery, proximal deep vein thrombosis and past history of pulmonary embolism. Indications for suprarenal placement of vena cava filters and results of such as procedure were discussed.
Pneumonol Alergol Pol 1995
PMID:[Implantation of a LGM suprarenal vena cava filter--case report]. 852 May 62

Although patients with thromboembolic disease frequently have family histories of thrombosis, well-defined defects such as inherited deficiencies of anticoagulant proteins are found only in minority of cases. Herein, we present a family study of 42 years old woman with recurrent deep vein thrombosis which occurred first time four years ago during pregnancy, in subclavian vein, in relation to cardiac stimulator implantation because of atrio-ventricular III(0) block. Her laboratory investigation demonstrated normal APTT time, prothrombin time, platelet number, antithrombin III and protein C activity. Plasma antiphospholipid antibodies contents was within the normal range. The result of activated protein C(APC) resistance test was abnormal (R=1.64). Family study revealed similar degree of APC-resistance defect in her DVT symptomatic mother and two healthy young daughters (R=1.73 and 1.54 respectively). Additionally, a slightly reduced total protein S plasma concentration was found in the patient and her two children. The influence of a slightly reduced protein S level on the results of APC-resistance was excluded by evaluation of normalized activated protein C sensitivity ratio (nAPC-SR) as described de Ronde and Bertina.
Pol Arch Med Wewn 1995 Dec
PMID:[Thrombophilia in a family with resistance to activated protein C and protein S deficiency]. 861 15


1 2 3 4 5 6 7 8 Next >>